This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck KGaA

Drug Names(s): somatropin injection

Description: Saizen [somatropin (rDNA origin) for injection] is therapeutically equivalent to the natural GH produced by the body, made by recombinant DNA technology. Saizen is indicated for the treatment of Growth Hormone deficiency in children and adults, Turner’s syndrome, chronic renal failure.

Deal Structure: In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.

Merck and Aeterna Zentaris
In May 2015, Aeterna Zentaris and EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA, announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen to designated medical professionals in specified territories in the United States.

Under the agreement, Aeterna Zentaris will detail Saizen to designated medical professionals. Payment to Aeterna Zentaris will be based on new, eligible patient starts on Saizen above an agreed-upon baseline.

Aeterna Zentaris and Ascend...See full deal structure in Biomedtracker

Partners: Besins Healthcare SA AEterna Zentaris, Inc.

Saizen News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug